UvA Ventures

ACE Incubator is a university startup incubator based in Amsterdam, jointly owned by four academic institutions: the University of Amsterdam, Vrije Universiteit, Hogeschool van Amsterdam, and Amsterdam UMC. It is dedicated to supporting researchers, scientists, students, and entrepreneurs with technology-driven ideas, helping them transform their concepts into viable businesses. The incubator hosts young entrepreneurs who are developing innovative solutions in sectors such as deep tech, medical and health technology, chemical and advanced materials, and sustainable technology. ACE provides a range of resources, including tailored programs, startup facilities, an extensive entrepreneurial network, and mentorship from experienced startup professionals, thereby facilitating the growth of ambitious science and high-tech entrepreneurs at all stages of their business journey.

Sigmascreening B.V. is a medical device company based in Amsterdam, Netherlands, specializing in the development of innovative products for breast cancer screening. Established in 2010 as a spin-off from the Academic Medical Center Amsterdam, Sigmascreening focuses on enhancing digital mammography, the recognized standard for breast cancer detection. One of its notable products is the Sensitive Sigma Paddle, designed to measure the mechanical properties of breast tissue during compression, thereby improving the accuracy and effectiveness of screening processes. The company is committed to advancing technology in the field of breast cancer diagnostics through its ongoing product development efforts.

InCatT specializes in contract research for catalyst development, serving various industries such as pharmaceuticals, flavors & fragrances, oil & gas, and fine chemicals. The company offers services including high-throughput screening, catalyst optimization, and scale-up studies.

Arthrogen is a biopharmaceutical company based in Amsterdam that focuses on developing local gene therapy for inflammatory diseases. The company utilizes viral-mediated gene transfer, specifically adeno-associated virus (AAV)-based therapeutics, to address various health conditions. Its primary emphasis is on treating rheumatic diseases, aiming to provide effective solutions for managing these inflammatory disorders. By specializing in the creation of viral gene therapy vectors, Arthrogen seeks to advance treatment options for health professionals dealing with inflammatory diseases.